Tag: BLUE

Positive sentiments for Bluebird Bio and VMWare

BLUE – Bluebird Bio Inc is focused on developing and commercializing drugs based on gene therapy to treat patients with genetic diseases and cancer.

BLUE – Bluebird Bio Inc

Fundamentals Previously closed at 47.72
Day’s high 51.46
Day’s low 47.61
P/E ratio NA
EPS -2.44

 

Analysts opinion Bluebird Bio announced that its ongoing phase 2 study evaluating the product candidate “Lenti-D” for the treatment of cerebral adrenoleukodystrophy (CALD) will be presented today at the American Academy of Neurology (AAN) Annual Meeting. The news for the investigational drug Lenti- D seems to be positive, with all patients remaining free of MFDs, and consistent safety-profile. The revenues for the stock is expected to be reported on May 4th, and analysts estimate EPS at $-1.19. Technically, bluebird has formed a double-bottom chart pattern, and is expected to be bullish.
Sentiments Also, Deutsche Bank AG and Bank of America Corp DE have boosted their stakes in BLUE and investor sentiment seems to be bullish.
Social Media Pulse The stock has 100% higher chatter than usual.

 

Continue Reading…

Bluebird Bio and Under Armour may see a positive sentiment in the long run

UA – Under Armour, Inc – last closed at $69.96 – Bullish (Long term)

Under Armour, a sportswear giant’s stocks fell about 11% yesterday, with the news of Morgan Stanley Downgrading the stock to “Sell”. Jay Sole, an analyst at Morgan Stanley, cut its stock price target for UA from $103 to $62. According to Jay Sole, the UA has changed its pricing, and marketing strategy. “UA has always competed on brand image and innovation, rarely on price. This change in trend is a major concern because this positioning threatens to erode UA’s premium brand image and ultimately its long-term growth potential.” he says.

A 2014 report from Sport Scan said Under Armour surpassed Adidas to become the No. 2 sportswear brand in the U.S., trailing only Nike Inc. Under Armour revenue at the company has grown at least 20 percent in 22 consecutive quarters. The revenue for Q3 has been looks good for the company.

The downgradation of the stock looks like the only reason for the stock price fluctuations. So, according to analysts, though the market sentiment is bearish, it might be short lived and the market would be bullish for long term investors.

Continue Reading…